oncosil
MEDICAL
ASX.OSL

Investor Update

Advancing Pancreatic cancer treatment
Transforming the prognosis

August 2020

Commercialising a breakthrough implantable radiotherapy treatment for pancreatic cancer

Investment Highlights

Proven world class technology: OncoSil™ is a unique and innovative platform technology with compelling clinical data for pancreatic cancer treatment - doubling of the median overall survival length and downstaging of previously unresectable patients – Platform technology can be leveraged into other indications (bile duct cancer, liver)

A clear global opportunity: >US$3bn market opportunity to become standard of care in combination with chemotherapy; solving global unmet need for pancreatic cancer patients where surgery is not a viable option

Ready to commercialise globally: Achieved milestone CE Mark approval and Breakthrough Device designation; ready to commercialise for launch in Europe, UK and Asia

Highly attractive and scalable operating model: Strong operating leverage with high gross margins when at scale, with a low fixed cost base - low cost salesforce and a highly scalable manufacturing and distribution capability in place

Best-in-class leadership team: Highly experienced board and management team with successful track record developing, licensing and commercialising early stage drugs

In 2020, OncoSil has continued to deliver upon its stated objectives

Stated objectives from the May 2020 capital raising achieved

Appointment of Nigel Lange (ex Sirtex Europe CEO) to drive European commercialisation	✓
Humanitarian Device Exemption (HDE) filing with FDA for Bile Duct Cancer	✓
Regulatory filing in Australia	✓
Regulatory clearance in Singapore	✓
Regulatory clearance in Malaysia	✓
Regulatory clearance in Hong Kong (expected later this year)	✓

Status ✓ Yes ✓ In part ✗ No

Upcoming catalysts

- **Expected first sale in UK/EU** –2H CY20
- **Regulatory decision in US for Bile Duct Cancer** – anticipated 4Q CY20
- **Regulatory clearance in Australia** –anticipated 1H CY21
- **Regulatory decision in Hong Kong** – anticipated 2H CY20

OncoSil Medical is a commercial-stage medical device company

Who are we

- Developing and commercialising its proprietary platform technology, OncoSil™
- OncoSil's first approved indication is in locally advanced pancreatic cancer
- Filed for humanitarian use indication of bile duct cancer in US

What is our technology

- Proprietary brachytherapy (internal radiation) medical device
- Implanted device (brachytherapy) delivering targeted radiation to pancreatic tumour
- Breakthrough device designation in US, Europe and parts of Australasia

What approvals have we received

- Approved to sell in UK, EU, Singapore, Malaysia and New Zealand
- Awaiting regulatory clearance in Australia and Hong Kong
- CE Mark approval
- Breakthrough designation in US, EU, UK and Singapore
- Patent protected across all key jurisdictions

What our data shows

PanCo trial results

- ✓ Excellent Local Disease Control
- ✓ Higher Disease Control Rate
- ✓ Prolonged Overall Survival
- ✓ Tumour reduction
- ✓ Encouraging rate of Surgical Resection with Curative intent
- ✓ Prolonged Progression Free Survival

Minimally invasive procedure and allows for targeted radiation

OncoSil™ Microparticles are suspended in a rheological Diluent



Endoscope guided (ultrasound) into the upper intestine



Using ultrasound imaging the needle is guided into the target lesion



OncoSil™ injected directly into the tumor. Implanted Microparticle localization shown on Bremsstrahlung imaging

Treating Pancreatic cancer is challenging and difficult

Existing treatments for pancreatic cancer are ineffective...



Late diagnosis

- Symptoms often unnoticed until cancer has metastasised

Sub-optimal current standard of care

Surgery - not feasible in 85% of patients

Chemotherapy - limited effectiveness and very toxic

Radiation therapy - toxic to the patient's GI tract

Limited advancements in past 20 years

- Only two drugs to have made significant improvements in pancreatic cancer; last approved in 2013
- Median overall survival has only increased by 2 months (to 8.5 months)

...resulting in very poor survival rates[1]

~8.5 months

Overall median survival

<5% chance

Reaching 5-year survival mark

Notes.

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

The OncoSil™ device provides a unique and effective solution

Radiation therapy delivered directly into the tumour

OncoSil™ has clinically proven to prolong median overall survival in LAPC patients





Reduction in the risk of death compared to CT-only and ICT + CCRT studies [2]



One-year survival rate in the per protocol population



Increase to 9.3 months in median PFS compared to CT-only and ICT + CCRT studies [2]

Survival length of ~16 months is based on data taken in May 2019, the time of the latest analysis

Notes.

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

(2) LAPC = Locally advanced pancreatic cancer; CT = Systemic Chemotherapy; ICT = Induction Chemotherapy; CCRT = Consolidated Chemotherapy

A clear market opportunity for OncoSil to become standard of care

There are more than 40k locally advanced pancreatic cancer (LAPC) cases p.a. in EU & UK [1,2]

		Disease prognosis	Current treatment	OncoSil solution
Future focus		**Resectable**	Surgery	OncoSil™ could be used to downstage tumours prior to surgery to improve surgical outcomes
Current focus		**Locally Advanced**	Chemotherapy Radiation therapy	OncoSil™ provides treatment to shrink tumours, reduce pain, downstage to surgery and prolong survival
Future focus		**Metastatic**	Chemotherapy	Unlikely to benefit overall survival but OncoSil™ may be used to control tumour growth, alleviate pain and improve quality of life

oncosil MEDICAL

Promising opportunity to become the standard of care

- ✓ A form of radiation therapy, to be used in combination with chemotherapy
- ✓ More concentrated radiation compared to external beam radiation
- ✓ Safer use than external beam radiation as it does not impact healthy tissue

Notes.
(1) GLOBOCAN 2018: Estimated Cancer Incidence Worldwide in 2018 (IARC/WHO)
(2) Based on LAPC cases equating to 40% of all pancreatic cancer cases

Targeting a >US$3bn, global unmet need in pancreatic cancer treatment

OncoSil's market opportunity for LAPC:

Target market	Commercialisation status	Pancreatic cancer incidences p.a [1]	Locally advanced pancreatic cancer [2]	Market opportunity (USD)[3]
UK (launch market)	Approved to sell	11,374	4,550	**~$115m**
European Union	Approved to sell	88,631	35,452	**~$890m**
Singapore	Approved to sell	855	342	**~$9m**
Malaysia	Approved to sell	976	390	**~$10m**
Hong Kong [4]	Approval pending	766	306	**~$8m**
ANZ	Australia – Approval pending NZ – Approved to sell	4,298	1,719	**~$40m**
China	Developing regulatory pathway to approval, designing trials Commercialisation via strategic partnerships	116,291	46,516	**~$1,160m**
Japan	Commercialisation via strategic partnerships	43,119	17,248	**~$430m**
United States	Breakthrough designation received, designing trials Targeting approval 2022/2023	50,846	20,338	**~$500m**

LAPC target market size >US$3bn p.a

Notes.
(1) GLOBOCAN 2018: Estimated Cancer Incidence Worldwide in 2018 (IARC/WHO)
(2) Based on LAPC cases equating to 40% of all pancreatic cancer cases; (3) Based on OncoSil list dose pricing of US$25,000
(4) Hong Kong Cancer Registry, Hospital Authority 2017. Accessed from https://www3.ha.org.hk/cancereg/allagesresult.asp

OncoSil's commercialisation strategy currently in full swing

Clear focus on first sales in Europe and entry into other markets

- **CE Mark granted** (Apr-20)
- Scalable manufacturing capabilities
- Sales force ramp up
- Multiple hospital sites being onboarded
- First revenues expected this year

EU / UK

ASEAN / APAC

- Approvals received to sell OncoSil™ device in Singapore, Malaysia and New Zealand
- Currently awaiting approvals in Australia and Hong Kong

Strategic Growth Pillars

- Dual entry pathway via LAPC and bile duct
- LAPC - FDA Breakthrough designation
- Bile duct - HDE filing submitted with outcome expected in 4Q 2020

US Market Entry

Strategic Partnerships

- OncoSil continues to explore all attractive opportunities, including potential licensing agreements and strategic partnerships with external parties

OncoSil well progressed across key markets



Europe – clear path to first revenues

Step by step plan to achieving first revenues

Clinical trials and evidence development	✓ Conducted lengthy and complex PanCO clinical trial ✓ Compelling results and safety data from trial underpinned CE Mark ✓ Increased awareness and buy-in through results, ongoing publications and support of key opinion leaders
Manufacturing and supply chain	✓ End-to-end manufacturing capabilities, supply chain and logistics in place and validated ✓ Capabilities highly scalable to meet commercial launch quantities
Regulatory approvals	✓ Obtained Breakthrough device designation ✓ Obtained CE Mark in April 2020
First Revenues[1]	✓ **Appointment of Nigel Lange, ex Sirtex Europe CEO, to drive European commercialisation strategy** ✓ **Focus is on winning and activating large key hospitals with a small and focused sales team** ✓ **Customer onboarding progressing strongly for top tier hospitals** ✓ **First revenues expected this year** ✓ **We expect strong network effect and strong sales growth once leading centres are activated**

Notes.
(1) Launch preparation is currently delayed due to the COVID-19 pandemic, with limited hospital access causing disruptions in new site initation, training, shipping and logistics.

Europe – repeatable sales model to increase penetration



CE Marking allows for the Oncosil device to be marketed and sold to hospitals in the EU and the UK

Strategically target experienced Tier 1 sites with high patient volume with focus to maximise utilisation per site

Engage in training with relevant practitioners so that decision makers can choose OncoSil when deciding treatment options

Build evidence and industry loyalty from growing number of successful treatments using the OncoSil™ device

Increase utilisation within hospital and add more hospitals to customer base through network effect

Notes.

(1) Launch preparation is currently delayed due to the COVID-19 pandemic, with limited hospital access causing disruptions in new site initation, training, shipping and logistics.

US – Expanding into new indications driving greater economies of scale

Bile duct pathway into US market reinforces OncoSil™ platform technology

	Bile Duct Cancer	Pancreatic cancer
Market opportunity	**US$80mn p.a[1]**	**US$500mn p.a[2,3]**
Route to US entry thus far	☑ **December 2018:** Humanitarian Use Designation (HUD) granted by FDA ☑ **July 2019:** Successfully agreed with FDA that PanCO data could be used as predicate for dCCA	☑ **August 2016:** Investigational Device Exemption (IDE) granted by FDA ☑ **March 2020:** Breakthrough Device designation granted by FDA, successfully meeting its strict criteria
Forward plan	☑ **July 2020:** HDE filing submitted Outcome expected in 4Q 2020	☐ **Now:** Working closely with FDA to optimise the Pre-market approval (PMA) evidence development and clinical trials
	Expansion into new indications	**Continues to be a core focus**

Notes.
(1) Based on OncoSil's target indicative list dose pricing of US$50,000 and the incidence of distal cholangiocarcinoma in the US
(2) GLOBOCAN 2018: Estimated Cancer Incidence Worldwide in 2018 (IARC/WHO)
(3) Based on OncoSil list dose pricing of US$25,000 and pancreatic cancer target market of 40% of incidences

US – Bile duct cancer market a critical part of OncoSil's US strategy

Decision to explore various US regulatory pathways

In October 2019, OncoSil announced its intention to explore additional US regulatory pathways outside of LAPC, forming OncoSil's dual entry pathway into US

HDE application submitted to FDA in July 2020

OncoSil recently submitted the Humanitarian Device Exemption (HDE) application to the FDA for the treatment of bile duct cancer

Commercialisation of bile duct cancer treatment

If successful, Oncosil will be able to sell its device in the US for the treatment of bile duct cancer, which has a market size of US$80m p.a[1].

Notes.
(1) Based on OncoSil's target indicative list dose pricing of US$50,000 and the incidence of distal cholangiocarcinoma in the US

Corporate Summary

OncoSil Medical Limited (ASX:OSL)

- Proprietary brachytherapy (internal radiation) medical device
- Developing and commercialising its proprietary paltform technology, ***OncoSil™*** ; anticipating first revenues in Europe
- Milestone CE Marking and Breakthrough Device designation to help accelerate commercialisation strartegy
- Patent protected in all major geographies

OncoSil Medical Limited (ASX:OSL)

Share price (26-Aug-20)	A$0.11
Number of shares	829m
Market capitalisation	**A$91.2m**
Net cash (30-Jun-20)	A$21.0m
Enterprise value	**A$70.2m**

Share price performance (1 year)

Important notice

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 30 April 2020.

Daniel Kenny
CEO & Managing Director
E: daniel.kenny@oncosil.com.au

OncoSil Medical Ltd
www.oncosil.com.au

T: +61 2 9223 3344
F: +61 2 9252 3988

oncosil
MEDICAL